Objective: Familial hypercholesterolemia (FH) is an autosomal dominant disease caused by mutations in the genes for LDL receptor (LDLR), apolipoprotein B (APOB) and Proprotein convertase subtilisin/kexin type9 (PCSK9). The purpose of the current investigation was to define the current spectrum of mutations causing FH in Israel.
Background
Familial Hypercholesterolaemia (FH, [OMIM #143890]) is a genetic disorder, inherited in an autosomal dominant fashion, characterized by the defective plasma clearance of low-density lipoprotein cholesterol (LDL-C), and may be caused by mutations in three genes: LDLR, APOB, and PCSK9 (1) . A recessive form of FH due to mutations in LDLRAP1 is also known (2, 3) . FH is estimated to affect 1 in 230-250 individuals (4) (5) (6) , and if untreated leads to premature coronary heart disease (CHD). Previous studies revealed that in several relatively isolated populations there is an increased frequency of FH (7) (8) (9) . In some subpopulations, specific LDLR mutations were found to be common (10) (11) (12) (13) (14) (15) (16) (17) .
Israel is comprised of many populations in which a founder effect has been well described, such as the Ashkenazi Jewish population, where the founder effect has been dated back to the 14 th century (15, 18, 19) . Two decades ago we reported all identified mutations in the Israeli population causing FH (20) . The LDLR gene was systematically screened for mutations using methods available at the time such as single strand conformation polymorphism (SSCP) and denaturing gradient gel electrophoresis (DDGE). Families of patients with clinical characteristics of FH based on the Simone Broome criteria were recruited through the MED-PED (Make Early Diagnosis Prevent Early Death) FH program (21) . Of the 192 families available for screening 15 different mutations were found in 81 individuals (42%). The FH patients harboring these 15 mutations originated from 10 countries (Israel, Hungary, Iraq, Russia, Lebanon, Lithuania, Morocco, Poland, Rumania and Syria). Since this publication, no systematic effort was made to expand our knowledge of FH-causing mutations in the Israeli population.
We tested for the mutation in the index cases of 67 newly recruited Israeli FH families as part of the MED-PED project (21) using high-throughput detection methods and Multiplex Ligationdependent Probe Amplification (MLPA) for exon deletions or insertions. However, it is well known that about 60% of clinically diagnosed FH patients are mutation-negative (4), and it was hypothesized that FH can also be caused by an accumulation of LDL-C raising alleles each having small contributive effect (22) . Using common variants affecting LDL-C concentration identified in the meta-analysis of genome-wide association studies by the Global Lipid Genetic Consortium (GLGC) (23), a gene score method based on twelve common LDL-C raising SNPs has been developed (23) and subsequently refined to include only 6 SNPs (30) . We therefore also genotyped our cohort for the effect of this 6-SNP score in our subjects.
Methods:

Recruitment of FH patients and families
Families of patients with clinical characteristics of FH are continuously recruited through the MED-PED (Make Early Diagnosis Prevent Early Death) FH program (21) . Inclusion criteria for the index cases are mostly based on hypercholesterolemia with a plasma LDL-C level above the 95th percentile for age and gender. Tendon xanthomas and history of premature (age under 60) ischemic heart disease in the patient or in a first-degree relative are recorded but are not required for recruitment. Biochemical determinations plasma triglyceride, total cholesterol and high density lipoprotein (HDL) cholesterol levels were determined using commercially available diagnostic kits (Boehringer Mannheim, Germany). Plasma LDL-C levels were calculated according to the Friedewald-Levy formula (24) . For patients where untreated lipid levels were unavailable, the treated lipid levels have been adjusted for the recorded dose and type of statin being used (see table 2 in Supplementary data).
Molecular Genetic Analysis
High Resolution Melt (HRM): Oligonucleotide primers for PCR-HRM were designed (25) to cover the promoter and coding regions of LDLR (intron-exon junctions and up to 40 bp of the intron) together with a fragment of exon 26 of APOB to cover the area for common mutation p.(R3527Q), and exon 7 of PCSK9 to cover p.(D374Y). Exon 10 of LDLR was screened by two overlapping PCR fragments and exon 4 by four overlapping fragments. PCR and subsequent HRM were carried out (25) using the Rotor-Gene 6000 (Qiagen) using AccuMelt HRM SuperMix (from Quanta BioScience, DNA-saturating dye; SYTO 9) with 25 ng of gDNA and 4 pmol per µl of each primer in a final volume of 10 μl.
Restriction Fragment Length Polymorphism (RFLP): The samples were genotyped for common polymorphisms in LDLR by RFLP and their genotypes compared with the HRM result as described in Whittall et al. 2010 (25) . Those with shifts due to polymorphism on the HRM were not examined further. However, samples without the polymorphism but with a shift were sequenced to find the cause of the melt temperature shift. The HRM-PCR products were used for digestion with the appropriate restriction enzyme (NEB (UK) Ltd. Hitchin, Herts) using 5 μl of HRM-PCR product and 3U of appropriate enzyme (supplementary Table S2 ) in a total volume of 15 μl and run on a 1.5% agarose gel in 1xTBE buffer.
Sequence Analysis: HRM-PCR products PCR products that showed a shift in the melt profile and melt temperature were Sanger sequenced. The DNA purification was performed using Illustra GFX PCR DNA and Gel Band Purification Kit (from GE Healthcare). The same primers used for HRM-PCR were used for sequencing, which was performed by Source BioSciences, LifeSciences. LDL-C gene score calculations for polygenic hypercholesterolaemia: To assess the polygenic cause of hypercholesterolaemia, patients were genotyped for 6 LDL-C raising SNPs based on recent findings (22, 23, 30) . KASPar PCR technique (Kbiosciences, UK Hoddesdon, Herts, UK) or TaqMan assays (Life Technologies, Carlsbad, California, US) and genotype calling for all assays was carried out using an automated system, the results of which were checked manually by study personnel using SNPviewer software. One SNP (rs4299376) could not be genotyped and a proxy was used instead (rs6544731). The LDL-C gene score was calculated using weighted. A group of 3,020 healthy volunteers (participants of the UK Whitehall II (WHII) study (31) was used for comparison.
Multiplex Ligation Dependent
Results:
The cohort of 67 unrelated index patients (36 men and 31 women) with an average age of 45±15 (youngest 10yrs, eldest 72yrs) were studied. A summary of the clinical characteristics and combined lipid data of the cohort is presented in Table 1 . For patients where untreated lipid levels were unavailable, the treated lipid levels have been adjusted for the recorded dose and type of statin being used. Overall, the mean serum total cholesterol was 7.48±1.89mmol/L (3.6 -15.0 mmol/L), and the mean serum LDL-cholesterol was 5.52±1.91 mmol/L (1.0 -13.1 mmol/L). 15 of the recruited patients have levels of untreated (or statin dose adjusted) LDL-C below the Simon Broome cut-off of 4.9mmol/l (supplementary Table 1 ) and are therefore strictly not subjects with a formal diagnosis of FH.
Mutations of the LDLR and APOB gene were found in 24 patients which comprises 36% of the cohort (table 2, and Figure 1 ). If the 15 subjects who do not confirm to the SB diagnostic criteria are excluded, (ie with LDL-C <4.9mmol/l) the overall mutation detection rate increases to 23/52= 46%. As expected, the mean total cholesterol and LDL-cholesterol (adjusted for statin use) was significantly higher in the group of patients with a mutation than in those without a mutation, (40% higher p= 0.02 for LDL-C and 32% higher p = 0.01 for TC). Among the twenty-four, 16 different LDLR mutations were found of which two were novel, and the p.(R3527Q) APOB mutation was also identified. This is the first reported APOB mutation carrier identified in the Israeli population. No PCSK9 mutations were identified. Two mutations, p.(G219del) and p.(D167H), which are founder mutations in Ashkenazi and Sephardic Jewish ethnic group respectively, were observed in two probands (Is681 and Is687) (20) . Three probands (IS 537, IS544, and IS 595) were found to carry a 10 base pair deletion (c.1570_1579del) in exon 10 of LDLR which leads to a frameshift change ending in a stop codon after twenty-one residues. This deletion, which was first seen in a Jewish Iraqi FH patient (20) (and was incorrectly described as a 9bp deletion), occurs in the EGF precursor homology domain of the LDLR and is predicted to be pathogenic.
Two novel LDLR mutations were identified: c.-191C>A in the promoter region, and p.(E140A), in exon 4. The relatives of these index cases were recruited to provide evidence for segregation of the mutations with elevated LDL-C (figure 2). In the pedigree shown in Figure 2A Figure 2B , for the p.(E140A) mutation, the co-segregation of the mutation with elevated LDL-C levels is shown in a three generation family. Two additional families were studied. Pedigree 2C is of a Druze family with the exons 7-14del mutation showing segregation of the mutation with the trait with 18 family members carrying the deletion and also having elevated TC/LDL-C. In the pedigree shown in p.(V827I) was found in 8 individuals in our cohort. This variant has been reported before as causing FH (32, 33). LDL-C levels in these subjects were 4.1, 4.8, 4.91, 5.38, 5.72 5.9, 6.2 and 6.5mmol/l (supplementary Table 1 ), with a mean of 5.4mmol/l suggesting a mild mutation.
However this mutation was found as a compound heterozygous mutation with p.(E140A) (above) with a clinical homozygous FH phenotype. To explore this further, we genotyped all the Israeli cohort for six common LDL-C raising SNPs previously reported, to see if polygenes could explain the increased LDL-C concentration in the no mutation group as well as the p.(V827I) group. Figure 3 presents the mean gene scores in the Israeli mutation-positive and mutationnegative groups, compared with those of healthy UK WHII cohort. The highest mean 6 SNP score was observed in the FH mutation negative group compared to the UK healthy control group (0.682 (0.14) vs 0.632 (0.22), p=0.03). We have estimated that FH mutation-negative patients who have the SNP score above the top quartile of the score distribution have a more than 95% probability of having their hypercholesterolaemia due to a polygenic cause (30) . Based on the WHII population 6 SNPs score top quartile (=0.51), in our study 36 out of the 41 mutation negative samples with sufficient genotyping data (87.8%) have a score above the cutoff, compatible with their hypercholesterolaemia having a polygenic and not a monogenic etiology. respectively, p = 0.9), not significantly higher than the control group (p=0.55). However, six out of the eight p.(V827I) carriers (75%) had a 6 SNP score above the top quartile cutoff. This finding suggests that the effect of the p.(V827I) variant on its own is insufficient to cause the full phenotype of FH, without an additional "polygenic" contribution.
Discussion.
The molecular detection and identification of mutant LDL receptor alleles is important from several aspects. First, it provides the only definitive diagnosis of FH. Second, the correct estimation of the prevalence of FH in a specific population is only possible through screening for the actual molecular defects. Third, it enables a high rate (50%) of screening success of first degree relatives of index cases, enabling early diagnosis and prevention of cardiovascular disease (34) . The Israeli population is very heterogeneous, consisting of a multitude of origin groups. In 1996 we published the first paper on the systematic mutation screening for FH patients (20) . In the current paper we report the results of mutation systematic screening of 67 new FH index cases recruited through the MED-PED project.
Our results show that the FH mutation spectrum in Israel has changed considerably over the last 20 years. We identified 16 different LDLR mutations and the first reported APOB p.R35227Q carrier in the Israeli population, with an overall mutation detection rate of 36%, rising to 46% if we apply the strict LDL-C cut-off suggested by the Simon Broome criteria. Previously (20) , we reported on mutation detection in 95 index cases, and detected 15 different mutations in 49 cases (detection rate 52%). Three mutations explained 34% of index cases, (Gdel219 (FH-Lithuania), D1687H (FH-Sephardic), and C681X (Lebanese)), and these were regarded as founder mutations in the three respective groups. Here we found only one individual with Gdel219 and one D168H and none with C681X, with the three most common mutations seen earlier now only explaining 8% of mutation carriers (2/24). We found two novel LDLR mutations. One variant in exon 4 p.(E140A), and a promoter variant, c.-191C>A, have not been seen in published literature, but both showed co-segregation compatible with being FH-causing. We also noted a probably novel major deletion of exons 7-14, found in a pedigree of Druze ancestry, although it is not possible to be absolutely certain that the deletion seen here is different from similar deletions reported previously (35) since break points have not been established. We found that a mutation p.(V827I), previously reported in subjects of Russian origin Russia (33) , to be the most common variant in our sample explaining 8/24 or 33% of the detected mutations. This variant was not seen previously in Israel and is likely to result from recent changes in the population demographics. In the group where no mutation was identified there is highly likely to be a polygenic cause of their elevated LDL-C and FH diagnosis, based on a 6-SNP gene score.
Pathogenicity of novel mutations
Individual Is556-03 is carrying the novel mutation, p.(E140A). It is predicted to be damaging by Individual Is697 carries a deletion of exons 7-14 as shown by MLPA analysis. We expanded the pedigree and demonstrated perfect segregation of the deletion with hypercholesterolemia. Thus, this major deletion seems to be a new LDLR mutation within the Druze population.
We also tested the available relatives of individual Is660 who is carrying the mutation p.(C121S) first reported in a UK patient in 2013 (57) but where little clinical data is reported. PolyPhen™, ™ and MutationTaster™ all predict the variant to be damaging and disease causing (Table 3) (26, 27, 29) . This mutation occurs in the ligand binding domain of the LDL-receptor, a cysteine repeat rich region that is important for disulphide bridge formation. The family tree could only be extended to one more individual carrying the mutation with a phenotype of FH. This substitution occurs in the tetrameric consensus sequence NPxY (where x is any amino acid) that plays a major role in the coated pit-mediated internalization of the LDL-receptor via interaction with the protein autosomal recessive hypercholesterolaemia (ARH) (38, 39) . The NPVY sequence in the cytoplasmic domain of the LDL-receptor is a major site of recognition for incorporation into clathrin-coated pits. The stringency at the third position (position p.827 "V") in this tetrameric sequence, is not as marked as that seen at the other three positions. Reduction in LDL-C cellular internalization index to approximately 65% of control values was seen when the valine of the NPVY sequence was replaced with an alanine or a cysteine (38) . However, data from the UCSC Genome browser conservation tab and PolyPhen's sequence alignment show the valine of the tetrameric sequence to be highly conserved across species.
One of the carriers of p.(V827I) is a compound heterozygote, and carries both p.(V827I) and p.(E140A) and has the phenotype of an FH homozygote. The LDL-C SNP score analysis showed that individuals who carry the variant have a similar SNP higher score to those who inherited other LDLR FH-causing mutations. However, one fact which suggests that the p.(V827I) variant is not FH-causing is that it is seen at a frequency of 0.00076 (92 carriers/121,374 alleles sequenced) in the ExAC database http://exac.broadinstitute.org/variant/19- 
11240278-G-A. While it is thus one of the more common mis-sense variants in the LDLR
Polygenic Familial Hypercholesterolaemia:
We genotyped the Israeli cohort for the 6 common LDL-C raising SNPs, based on the score suggested by Talmud et al and refined by Futema et al (22, 30) . Effects were similar to those published previously, with a found a significantly higher score in mutation-negative cases compared with the normal Caucasian cohort, with the score suggesting that a polygenic etiology is the likely explanation for the hypercholesterolaemia in ~90% of the mutation negative subjects.
. This score was validated before in several European mutation negative FH patient cohorts and found to be consistently higher than in the UK general Caucasian population reference group, and with no significant difference in score between the various FH cohorts (30) . Since the patients studied here are of the same ethnic background as the UK sample used previously, the comparison is unlikely to be confounded by ethnicity.
In such "polygenic hypercholesterolaemia" patients, first degree relatives are less likely to have high LDL-C than in mutation-positive patients. Thus, for successful screening of first degree relatives of FH patients, it is likely to be cost effective to ascertain that the index individual carries a known FH-causing mutation. By contrast, whole genome or exome sequencing in the low SNP score no-mutation patients may reveal novel genetic causes of FH.
Our study has some limitations. While we have previously demonstrated that HRM is a sensitive and specific technique (25) for mutation detection in FH patients, we acknowledge that Next Generation Sequencing (NGS) is now the preferred method of choice for molecular diagnosis, but this work was commenced in 2013 when such methods were not widely available and NGS is still an expensive technique and beyond the funds available for this research project. The overall mutation detection rate in our sample is relatively low compared with other similar published cohorts. (40) (41) (42) , although similar mutation detection rates were recently reported in Korea (43) . This may be because our inclusion criteria were less stringent than in other studies resulting in fewer "monogenic" FH patients and a lower mutation detection rate, and exclusion of those with LDL-C below the diagnostic threshold of 4.5mmol/l increased the mutation detection rate to 46%. This may, however, also be because of population differences in FH mutation prevalence. Also, while we screened the regions of the PCSK9 and APOB genes known to contain pathogenic mutations (25) , it is possible that a small proportion of patients may have mutations in the exons not covered here. While pathogenic variants in other regions of APOB have been reported (44) these are very rare. Similarly, gain-offunction FH causing mutations in PCSK9 are also rare, for example explaining less than 2% of FH patients in the UK, and none have been found in Israel. We therefore estimate that complete coverage of these two genes may at best have increased the overall detection rate by 2-3%. Finally, a limitation of the conclusion that the mean LDL-SNP score in the no-mutation subjects is significantly higher than in healthy controls is that we do not have a comparison group of healthy Israeli subjects and have used a sample of UK healthy controls. Since both groups are of European origin and both are white Caucasians we believe it is unlikely that the result is a false positive, and the mean score in the mutation positive subjects is similar to that in the UK healthy group as has been reported for other mutation positive patients (22, 30) .
Conclusion
The FH mutation spectrum in Israel has changed very considerably over the last 20 years. While a sample of 67 patients attending a single lipid clinic in Jerusalem will not be fully representative of all Israeli FH subjects, we clearly show that the current mutation distribution is very different compared to the 1996 study. It is likely that a much larger sample would find a wider range of mutations (both reported and novel), and also possible that patients from lipid clinics in other metropolitan centres may have a different mixture of Ashkenaz, Sephardic and Palestinian-Arab subjects. (RONEN IS THIS OK??)
The most common mutation in the FH patients was p.(V827I) which appears to be of mild effect.
In the vast majority of subjects were no mutation could be identified, there is likely to be a polygenic cause of their elevated LDL-C and FH diagnosis. These data can help design a future strategy for early screening for FH in our population. 
